Using a small molecule inhibitor of Apelin/APJ effectively inhibits the Apelin-PI3K/Akt signaling pathway and HCC growth in vitro and in vivo (Chen et al., 2019). The gene discussed is APLNR; the disease is hepatocellular carcinoma.